Cytiva (CEVEC) is a leading provider of high-performance cell technology for manufacturing advanced biotherapeutics from research and development to production scale. The company's product portfolio includes various platform technologies for gene therapy vectors, vector vaccines, and complex recombinant proteins. In the area of viral vectors, ELEVECTA® is the technology of choice for producing AAV. For RCA-free adenovirus vectors, CAP® Ad technology is the perfect solution. CAP® Go is the solution for producing complex and highly glycosylated recombinant proteins.